Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹57.93down ₹1.22 (2.06%)BSE ₹58.50
Share price at the NSE close on 29 Oct 2026. Previous close ₹59.15.
29 Oct: open ₹59.95, high ₹61.78, low ₹56.84
52-week range of traded prices to 29 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹125 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,69370.2% delivered
Krebs Biochemicals and Industries results
69 filed, newest first. Page 2 of 2.
Aug 2015
May 2015
Feb 2015
Aug 2014
May 2014
15 May · Results
Feb 2014
13 Feb · Results
Nov 2013
Aug 2013
29 Aug · Results
May 2013
Feb 2013
Nov 2012
Aug 2012
May 2012
17 May · Results
Feb 2012
Nov 2011
Nov 2010
May 2010
4 May · Results
The Company's Board of Directors are considering the Audited Results for the Financial year 2009-10 instead of Un-audited Results for the last quarter of the Financial year 2009-10
Apr 2009
13 Apr · Results
The Board of Directors of KREBS BIOCHEMICALS AND INDUSTRIES LIMITED have decided to take on record and publish the Audited Financial Results for the year ending 31st March, 2009 on or before 30th June, 2009 instead of the Unaudited Financial results for the quarter ending 31st March, 2009. Hence, no Board meeting would be convened for taking in record the Unaudited financial results for the quarter and year ended 31st March , 2009